for biologic therapy. Seven of the currently available biologics are registered for first-line use in RA, and systemic reviews suggest that these biologics have similar efficacies. [3, 4] The choice of drug depends on the side-effect profile, disease characteristics, patient preferences for route of administration, and cost. Because of the high risk of tuberculosis (TB) in SA, particularly associated with TNFi, biologic drugs with an alternative mode of action may be the most appropriate choice as first-line therapy. [5] In addition, certain disease features may guide the choice of drug, e.g. rheumatoid factor-negative patients are less likely to respond to rituximab, and those with pronounced systemic symptoms (such as anaemia of chronic disorders, high C-reactive protein and fatigue) are likely to have a good response to ANCA = anti-neutrophilic cytoplasmic antibody; AS = ankylosing spondylitis; CD = Crohn's disease; CLL = chronic lymphocytic lymphoma; GCA = giant cell arthritis; GI = gastrointestinal; IL = interleukin; IV = intravenous; JIA = juvenile idiopathic arthritis; NHL =non-Hodgkin lymphoma; PAED = paediatrics; PMR = polymyalgia rheumatica; PS = psoriasis; PsA = psoriatic arthritis; RA = rheumatoid arthritis, RS3PE = relapsing seronegative symmetrical synovitis with pitting oedema; mab = monoclonal antibody; SC = subcutaneous; SJIA = systemic juvenile idiopathic arthritis; SLE = systemic lupus erythematosus; SScL = systemic sclerosis; TNF = tumour necrosis factor; UC = ulcerative colitis. *Registration pending. †
Currently not available in South Africa.
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tocilizumab. Methotrexate or leflunomide should be co-prescribed with biologics, except in the case of tocilizumab, where there is good evidence for monotherapy. The Janus kinase (JAK) inhibitor tofacitinib is a new synthetic DMARD with equivalent efficacy to the biologic agents used in the treatment of RA, but it is not yet registered in SA.
Ankylosing spondylitis
The TNFi drugs dramatically improve the symptoms and reduce the radiographic progression of AS. Randomised controlled studies of all four TNFi have shown good efficacy in early and advanced disease.
Younger age, shorter disease duration, high inflammatory markers, human leukocyte antigen (HLA) B27 positivity and minimal baseline functional disability are associated with better outcomes. [6] Loss of response to TNFi over time is well documented in AS, probably related to TNFi antibody production. In these patients, switching to an alternative TNFi may be efficacious. Other biologics (rituximab, abatacept and tocilizumab) have shown only limited success in AS. In future, secukinumab (an interleukin (IL)17A inhibitor) may be useful.
Psoriasis
Persistent severe plaque psoriasis resistant to standard therapies is an indication for TNFi therapy. [2] Similarly, PsA (including peripheral arthritis, axial disease, enthesitis and dactylitis) has shown a rapid and significant response to TNFi with inhibition of radiographic disease progression. [7] More recently, ustekinumab, an IL-12/IL-23 monoclonal antibody, has been shown to be effective in psoriasis and PsA, but is currently only registered for plaque psoriasis. In addition, drugs inhibiting IL-17 seem promising, particularly for skin disease and enthesitis. [8] 
Inflammatory bowel disease
In Crohn's disease, monoclonal antibodies that inhibit TNF (but not TNF receptor blockers) are beneficial in steroid-refractory, steroid-dependent, or complex fistulising disease. This induction therapy needs to be continued for at least 12 months in patients who show a response. [9] The TNFi is usually prescribed together with an immunosuppressive agent, with evidence particularly favouring azathioprine. [10] Similarly, TNFi are also effective for treatmentrefractory, moderate, or severely active ulcerative colitis. Patients with IBD-associated axial or peripheral arthritis refractory to sulfasalazine may also benefit from TNFi. Ustekinumab has been shown to be useful in TNF-resistant Crohn's disease. [11] Abatacept and natalizumab (an integrin receptor antagonist) may also be effective in Crohn's disease and trials are ongoing.
Juvenile idiopathic arthritis
Biologic drugs have greatly improved outcomes in refractory polyarticular and oligoarticular juvenile idiopathic arthritis (JIA), and TNFi have been the most widely studied biologics in these diseases. A recent systematic review demonstrated that etanercept, adalimumab and abatacept were equally efficacious. [12] Refractory systemic JIA has shown good response to tocilizumab, and to IL-1 inhibitors including anakinra, canakinumab and rilonocept and encouraging study results have been reported with tofacitinib. The IL-1 inhibitors and tofacitinib are not yet licensed in SA.
Systemic lupus erythematosus
Despite initial optimism that biologic drugs would lead to new therapeutic options, most clinical trials in SLE have missed their primary endpoints. [13] Belimumab inhibits B-cell activation factor, which is also known as B-lymphocyte stimulator. It has been shown to reduce flares and antibody titres in mild to moderate SLE (excluding renal or central nervous system (CNS) involvement) and is the only biologic registered in the USA for use in SLE. Rituximab (for haematological, renal and CNS involvement), abatacept (for arthritis), and TNFi (for skin and joint disease) have been successfully used off-label.
ANCA-associated vasculitis, uveitis and Behçet's syndrome
Rituximab is one of the few biologics to have been studied in antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis, and has been shown to be non-inferior to cyclophosphamide for induction therapy. [14, 15] Although no randomised controlled trials have been published, observational studies have shown benefit in cyclophosphamideresistant disease. In refractory Behçet's disease, both TNFi infliximab and adalimumab were effective, also for severe ocular inflammation, whereas etanercept was less effective for ocular or gastrointestinal manifestations. [16] IgG4 sclerosing-related disease Immunoglobulin (Ig) G4-related disease is a rare, recently characterised, immune-mediated fibrosing disorder, with varying clinical manifestations depending on the specific organ system involved. Mainstay treatment is corticosteroids, but immunosuppressants may be added in relapsing patients or as steroid-sparing agents. Rituximab may be useful in refractory patients. [17] Adverse effects of biologics While the efficacy of biologic drugs has been clearly established, the risk of adverse effects has been uncertain, and has only recently been clarified by Cochrane meta-analysis and by literature review. [18, 19] Table 1 summarises the major adverse effects of various biologics available in SA. A great concern with all biologic treatments, with the exception of abatacept, is the increased risk of community-acquired and opportunistic infections. Of particular importance in SA is the risk of TB infection or reactivation, which is only partially addressed by screening for latent TB infection and isoniazid prophylaxis. In studies conducted in countries with a low TB prevalence, the risk of TB seems highest among patients receiving monoclonal TNFi during their first year of treatment and rises as high as a 56-fold increased incidence compared with the general population. [20] [21] [22] Although initially of concern, malignancies do not seem to increase in patients using biologics except for a possible increase in melanoma associated with TNFi. [23] 
Switching and withdrawing biologic therapy
Despite impressive results in the majority of patients, response to a specific biologic drug is unpredictable and up to one-third of patients with an autoimmune disease requiring biologic therapy have a poor response or lose their response. These patients may respond to switching to another biologic drug. The search for biomarkers to allow optimal selection of biologic drugs is ongoing.
Given the costs and potential adverse effects, withdrawal or reduction of biologic therapy is a goal of many patients and physicians. In RA, AS and PsA, this may be possible in a subset of patients who have achieved long-term remission, particularly in those with early disease, and studies are ongoing. [24] In the case of IBD, withdrawal of TNFi therapy in patients who have been in clinical remission ≥12 months appears safe in the majority of patients.
Vaccination
Because of the increased risk of serious infections in patients using biologics, vaccination is an important preventive strategy. [25, 26] Current recommendations are that vaccines, particularly influenza and pneumococcal vaccines, be given prior to biologic therapy where possible, and that live vaccines (including measles, mumps, rubella, live attenuated influenza, varicella zoster, yellow fever, Ty21a oral typhoid, bacillus Calmette-Guérin (BCG), and rotavirus vaccines) are contraindicated. [27] 
Cost of biologic drugs
One of the major problems restricting biologic use in SA is their cost, ranging between R110 000 and R160 000 annually. Offset against this cost is the benefit of early disease control, thus reducing the impact of the disease on functional capabilities and work productivity. A recent French study demonstrated that even though early biologic therapy in RA was costly, it resulted in lower health-associated costs (including physician consultations, investigations and hospitalisation) over a 4-year period owing to better disease control. [28] Long-term studies in SA are needed to evaluate the cost of biologics against the economic burdens of poorly controlled disease.
Healthcare providers and patient groups in SA need to lobby for wider access to biologics for patients who require them, in both the private and state sectors. This might entail pharmaceutical companies offering drugs at reduced prices, greater flexibility by medical schemes for patients with limited cover, and the use of biosimilar drugs.
Biologic registries
Biologic registries are a major source of efficacy and safety data, and a registry of rheumatology patients who are on biologic therapy has been in operation in SA since 2008. A recent paper describes the SA experience of TNFi therapy in RA, showing results similar to those seen elsewhere in the world. [29] Further clinical research, using the epidemiological data from the SA registry, will help to develop evidence-based treatment guidelines with regard to TB risks and latent TB detection, strategies to monitor patients on biologics, and long-term cost-effectiveness of treatment.
Conclusion
Ben Parker, uncle to Peter Parker aka Spiderman, remarked 'With great power comes great responsibility' . So it is with biologic drugs. As our knowledge of the underlying mechanisms of autoimmune diseases expands, we can expect more targeted therapies to be developed. Our growing experience with biologics and their adverse events will include development of clinical and laboratory biomarkers to allow selection of optimal therapy for each patient. The current and future challenges in SA are to optimise the standard care for patients with autoimmune diseases, with careful selection of patients with severe refractory disease and provision of the appropriate biologic drugs.
